Maraviroc (MVC)

DRUG3 trials

Sponsors

International Maternal Pediatric Adolescent AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID), HealthBio, Inc.

Conditions

HIV InfectionsLong COVID

Phase 2

Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long COVID-19/Post-Acute Sequelae of COVID-19 (PASC).

Not yet recruitingNCT06974084

HealthBio, Inc.Long COVID

Start: 2025-09-01End: 2026-04-30Target: 252Updated: 2025-05-15

Phase 4

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

CompletedNCT02519777

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2016-04-21End: 2021-01-05Updated: 2022-04-22

Unknown Phase

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

CompletedNCT00977756

International Maternal Pediatric Adolescent AIDS Clinical Trials GroupHIV Infections

Start: 2002-08-31End: 2014-03-31Updated: 2015-08-07